Stockreport

Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update

Chemomab Therapeutics Ltd. - American Depositary Shares  (CMMB) 
PDF -Completed Successful FDA End-of-Phase 2 Meeting Following Positive Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis (PSC)- -Achieved Alignment [Read more]